Alkem Laboratories has completed the acquisition of a 51-55% stake in Swiss medical device manufacturer Occlutech Holding AG through its wholly owned subsidiary, Alkem Medtech Private Limited. The transaction, executed pursuant to a Share Purchase Agreement, results in Occlutech becoming a step-down subsidiary of Alkem Laboratories. The disclosure was submitted to the stock exchanges under Regulation 30 of the SEBI LODR Regulations.

To facilitate this acquisition, Alkem Laboratories had previously infused capital into Alkem Medtech. This involved the acquisition of 79,36,50,794 equity shares for a total cash consideration of ₹1,100 crore via a rights issue at an allotment price of ₹13.86 per share. The shares were allotted on July 15, 2026.

Financial Details of the Transaction

The following table outlines the key financial metrics related to the capital infusion for the acquisition:

Background of Alkem Medtech

Alkem Medtech is a wholly owned subsidiary of Alkem Laboratories in India. Incorporated on March 27, 2024, the entity operates in the medical device sector with a focus on cardiovascular and orthopedic fields. For the financial year ended March 31, 2026, Alkem Medtech reported a turnover of ₹15.13 crore, compared to nil in the previous financial year. The subsidiary is strategically positioned to support the company's expansion into the medical device segment.

Alkem Laboratories Limited will convene an Extraordinary General Meeting (EGM) on August 17, 2026, to consider and approve the scheme of amalgamation with its wholly-owned subsidiary, Adroit Biomed Limited. The meeting is being held pursuant to an order dated June 10, 2026, passed by the Hon’ble National Company Law Tribunal (NCLT), Mumbai Bench. The amalgamation aims to consolidate the operations of the transferor company, Adroit Biomed, into Alkem Laboratories, the transferee company.

The scheme, approved by the respective boards of Alkem Laboratories and Adroit Biomed on February 13, 2026, and February 11, 2026, proposes that all properties, assets, and liabilities of Adroit Biomed will vest in Alkem Laboratories upon the scheme becoming effective. As Adroit Biomed is a wholly owned subsidiary, no new shares or cash consideration will be issued by Alkem Laboratories for the amalgamation. The shares held by Alkem Laboratories in Adroit Biomed will stand cancelled.

Meeting and Voting Details

The EGM will be conducted through video conferencing (VC) or other audio-visual means (OAVM) on Monday, August 17, 2026, at 11:00 a.m. IST. The deemed venue for the meeting is the registered office of Alkem Laboratories at Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai. Mr. Harihar Prakash Chaturvedi, Former NCLT Member, has been appointed as the Chairperson of the meeting, and Mr. Ritul Parmar, Practicing Company Secretary, has been appointed as the Scrutinizer.

Equity shareholders of Alkem Laboratories as on the cut-off date of August 10, 2026, are eligible to vote. The company has provided a remote e-voting facility, which will commence on August 12, 2026, at 9:00 a.m. IST and conclude on August 16, 2026, at 5:00 p.m. IST. Shareholders who have not voted remotely may also vote during the meeting via the e-voting facility available through VC/OAVM. The resolution requires approval by a majority of persons representing three-fourths in value of the equity shareholders.

Key Meeting Dates

Rationale and Approvals

The amalgamation is intended to integrate and consolidate business operations, providing operational rationalization and organizational efficiency. It is expected to eliminate duplication of work, reduce overheads, and allow for more efficient capital allocation. The scheme is conditional upon the approval of the requisite majority of shareholders and the subsequent sanction of the NCLT and other regulatory authorities.

The statutory auditors of both companies have confirmed that the accounting treatment proposed in the scheme is in conformity with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013. The notice of the meeting, along with the explanatory statement and the draft scheme, is available on the company's website and has been sent to shareholders.